You searched for "foundation"

2578 results found

Google searches predict pathology after a solar eclipse

This light-hearted review identified that the Google search term, ‘my eyes hurt’ was trending on 8 April 2024, coinciding with the exact time when a total solar eclipse passed over the US. They identified the subregions that searched this term...

Congenital nasolacrimal duct obstruction in patients with craniofacial abnormalities

This is a retrospective study including 1998 patients over a period of 10 years. Of this number, 41 patients were identified as having a craniofacial abnormality and congenital nasolacrimal duct obstruction (CNLDO) (23.1 per 10,000 live births). Interestingly the most...

Congenital nasolacrimal duct obstruction in trisomy 21 vs non-trisomy 21 patients

This is a retrospective case review study looking at patients who underwent intervention for congenital nasolacrimal duct obstruction (CNLDO) between January 2017 and January 2018. The authors state that patients were excluded if there was less than 60 months of...

Suitability of online materials for strabismus

In this study, the authors aimed to evaluate and compare online materials about strabismus using expanded metrics including readability, complexity and suitability. They highlight areas of improvement for better counselling of patients on the internet. Ten top web pages were...

Strabismus prevalence in a Pakistan population

The aim of this study was to compile the available literature reporting the prevalence of strabismus in Pakistan and calculate the pooled prevalence of strabismus in the Pakistan population. Meta analysis was conducted with 10 studies with a total of...

WATCH EPISODE 8: Beyond 2020 with the Andean Medical Mission

This video is for medical teams and NGOs who are working to eliminate avoidable blindness in remote village settings where the risk of an infection post-surgery is high.

Nordic Pharma Announces CE Mark Approval for Lacrifill® Canalicular Gel, Paving the Way for European Launch

Nordic group B.V – an international pharmaceutical company operating as Nordic Pharma have received CE mark approval for Lacrifill®, a novel dry eye therapy. Lacrifill® is a cross-linked hyaluronic acid gel that temporarily blocks tear drainage by occluding the canalicular...

Typical or surprisingly uncharacteristic presentations of neuro-ophthalmic emergencies

Irrespective of geographical location or patient cohort, emergency departments are high risk locations capable of inspiring extreme anxiety and dread in patients and doctors alike. The stress multiplies when a walk-in or referred case is suspected of underlying neurological pathology....

Myasthenia gravis presenting with isolated ptosis: a poorly studied subgroup

Investigation into the cause of one isolated symptom or sign can be challenging if that particular sign may be caused by a variety of pathological processes, affecting different tissues, and presenting to different specialties. Unilateral ptosis is a case in...

Retinoblastoma management update (part 2): treatment, screening and surveillance, long-term follow-up and new developments

Retinoblastoma treatment requires significant multidisciplinary input, but early detection through raising awareness remains key to improving outcomes. In the second article of a two-part series, Manoj Parulekar discusses retinoblastoma management, screening and research. This article has been published in two...

The role of injection assistant devices in establishing a nurse-led AMD service

The author shares his experience of setting up a nurse-led service to deliver anti-VEGF intravitreal injections and how injection assistant devices supported training. Age-related macular degeneration (AMD) has become a leading cause of irreversible blindness [1]. It is estimated that...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...